Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to ...
Silence Therapeutics rises on trial results and funding updates; Read on to see Divesiran’s outlook vs. Takeda’s rusfertide ...
The result from Merck-Moderna partnership validates years of research into mRNA-based therapeutic cancer vaccines.
Moderna (MRNA) stock surged 58% premarket following Phase 3 trial success showing its mRNA melanoma vaccine plus Keytruda ...
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
Moderna shares surge as personalised mRNA cancer vaccine with Merck's Keytruda cuts melanoma recurrence and spread in ...
Moderna shares surged after its personalised mRNA cancer treatment met key Phase 3 trial endpoints in melanoma with Merck's ...
A WOMAN who had a recurring cough and a hoarse voice was shocked to discover she had lung cancer, despite never having smoked ...
In a rare pair of papers published back-to-back in the journal Genes & Development, research teams led by senior author Anindya Bagchi, PhD ...
The science continues to mount on pesticides as drivers of microbial resistance, threatening biodiversity and ecosystem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results